On April 29, 2025, Juncell Therapeutics announced that the research results of the innovative process development for its tumor-infiltrating lymphocyte (TIL) therapy will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), to be held from May 13 to 15 (Central Time, USA).

Leveraging Juncell's robust feeder cell-free culture process, sufficient and highly active TIL cells can be obtained from various hot tumors and cold tumors without the need for high-concentration IL-2. Data show that these TIL cells have demonstrated significant antitumor effects in both syngeneic patient-derived organoids (PDO) and patient-derived xenograft (PDX) models. The research results provide a new perspective for TIL therapy—enhancing safety by eliminating IL-2 dependence and reducing costs by removing feeder cells.

Abstract Details:

Title: Development of A Feeder-Free Process for IL-2-Independent TIL Expansion

Poster Number: AMA362

Date and Time: May 15, 2025, 5:30 PM–7:00 PM

Location: Poster Hall Hall I2